Amarin just announced REDUCE-IT pre-specified subgroup analysis data to be presented at this year's AHA. The data sounds pretty impressive (caveat of mineral oil placebo, but I won't get into that now). My main point is that data from clinical trials doesn't always roll out in its entirety right away. It's been over 13 months since REDUCE-IT first announced top-line data and they are still presenting new stuff. So it would not be unusual at all for it to take seveal months for the BETonMACE data to roll out, even if it extends well into 2020.

REDUCE-IT® USA Results, in Prespecified Subgroup Analyses of Landmark REDUCE-IT Global Study, Showed Robust Cardiovascular Risk Reductions Across a Variety of Study Endpoints, Including Cardiovascular Death and All-Cause Mortality

https://investor.amarincorp.com/news-releases/news-release-details/reduce-itr-usa-results-prespecified-subgroup-analyses-landmark

REDUCE-IT USA: Results From the 3,146 Patients Randomized in the United States

https://www.abstractsonline.com/pp8/#!/7891/presentation/40313

They're also presenting a late breaker at AHA on their EVAPORATE study looking at effect of Vascepa on plaque volume/composition. It's a different session from BETonMACE so no conflicts.

BDAZ